NZ575425A - Aerosol formulation for the inhalation of beta agonists - Google Patents
Aerosol formulation for the inhalation of beta agonistsInfo
- Publication number
- NZ575425A NZ575425A NZ575425A NZ57542507A NZ575425A NZ 575425 A NZ575425 A NZ 575425A NZ 575425 A NZ575425 A NZ 575425A NZ 57542507 A NZ57542507 A NZ 57542507A NZ 575425 A NZ575425 A NZ 575425A
- Authority
- NZ
- New Zealand
- Prior art keywords
- acid
- hydroxy
- medicament formulation
- medicament
- formulation according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 146
- 238000009472 formulation Methods 0.000 title claims abstract description 109
- 239000000443 aerosol Substances 0.000 title description 21
- 229940125388 beta agonist Drugs 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 84
- 239000013543 active substance Substances 0.000 claims abstract description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 229910001868 water Inorganic materials 0.000 claims abstract description 33
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 15
- -1 methoxy, ethoxy Chemical group 0.000 claims abstract description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- 239000000460 chlorine Substances 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims abstract description 11
- 150000001450 anions Chemical class 0.000 claims abstract description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 9
- 239000011737 fluorine Substances 0.000 claims abstract description 9
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims abstract description 7
- 229960003728 ciclesonide Drugs 0.000 claims abstract description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 5
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 5
- 229960004436 budesonide Drugs 0.000 claims abstract description 5
- 230000000241 respiratory effect Effects 0.000 claims abstract description 5
- 150000001768 cations Chemical class 0.000 claims description 45
- 239000002585 base Substances 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 37
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 17
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical group C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 229960000257 tiotropium bromide Drugs 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- 239000008139 complexing agent Substances 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 6
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 5
- 229960001860 salicylate Drugs 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 229940093915 gynecological organic acid Drugs 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 description 43
- 239000004033 plastic Substances 0.000 description 23
- 229920003023 plastic Polymers 0.000 description 23
- 239000007788 liquid Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 19
- 229910052751 metal Inorganic materials 0.000 description 17
- 239000002184 metal Substances 0.000 description 17
- 150000004677 hydrates Chemical class 0.000 description 16
- 239000002131 composite material Substances 0.000 description 13
- 238000007789 sealing Methods 0.000 description 12
- 239000012530 fluid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 238000009792 diffusion process Methods 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 239000003570 air Substances 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical class [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 206010006451 bronchitis Diseases 0.000 description 5
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical class C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000003466 welding Methods 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 150000001649 bromium compounds Chemical class 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229950005583 flutropium Drugs 0.000 description 3
- 229960002462 glycopyrronium bromide Drugs 0.000 description 3
- 125000005635 hydromethanesulphonate group Chemical group 0.000 description 3
- 229960001888 ipratropium Drugs 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 229960000797 oxitropium Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 229940110309 tiotropium Drugs 0.000 description 3
- 229960001491 trospium Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OJWYYSVOSNWCCE-UHFFFAOYSA-N 2-methoxyethyl hypofluorite Chemical compound COCCOF OJWYYSVOSNWCCE-UHFFFAOYSA-N 0.000 description 2
- FLIKHGRDOOGIAS-UHFFFAOYSA-N 4-[4-[2-[[2-hydroxy-2-(6-hydroxy-3-oxo-4h-1,4-benzoxazin-8-yl)ethyl]amino]-2-methylpropyl]phenoxy]butanoic acid Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(OCCCC(O)=O)C=C1 FLIKHGRDOOGIAS-UHFFFAOYSA-N 0.000 description 2
- NUQXAUKMOUSMTC-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(3,4,5-trifluorophenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC(F)=C(F)C(F)=C1 NUQXAUKMOUSMTC-UHFFFAOYSA-N 0.000 description 2
- BGYAOSLJUWGONG-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(3-methylphenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 BGYAOSLJUWGONG-UHFFFAOYSA-N 0.000 description 2
- XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical compound O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 description 2
- NTBNTDZWIRYSNZ-UHFFFAOYSA-N 8-[2-[[1-(2,5-difluoro-4-methoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=C(F)C(OC)=CC(F)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 NTBNTDZWIRYSNZ-UHFFFAOYSA-N 0.000 description 2
- LLIIRCTZEHLXMG-UHFFFAOYSA-N 8-[2-[[1-(2,6-difluoro-4-methoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound FC1=CC(OC)=CC(F)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 LLIIRCTZEHLXMG-UHFFFAOYSA-N 0.000 description 2
- QFXSLFJLUFBYMN-UHFFFAOYSA-N 8-[2-[[1-(3,4-dichlorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(Cl)C(Cl)=C1 QFXSLFJLUFBYMN-UHFFFAOYSA-N 0.000 description 2
- ZYOTYURVSGBZNB-UHFFFAOYSA-N 8-[2-[[1-(3-chloro-4-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C(Cl)=C1 ZYOTYURVSGBZNB-UHFFFAOYSA-N 0.000 description 2
- CUTPRGMUKBUUQS-UHFFFAOYSA-N 8-[2-[[1-(4-bromophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(Br)C=C1 CUTPRGMUKBUUQS-UHFFFAOYSA-N 0.000 description 2
- QYNJVTWMKPJWTL-UHFFFAOYSA-N 8-[2-[[1-(4-chloro-2-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(Cl)C=C1F QYNJVTWMKPJWTL-UHFFFAOYSA-N 0.000 description 2
- PNOHOHBHZBYEIQ-UHFFFAOYSA-N 8-[2-[[1-(4-chloro-2-methylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(Cl)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 PNOHOHBHZBYEIQ-UHFFFAOYSA-N 0.000 description 2
- OJDNYNNILNAEEV-UHFFFAOYSA-N 8-[2-[[1-(4-chloro-3-methylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=C(Cl)C(C)=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 OJDNYNNILNAEEV-UHFFFAOYSA-N 0.000 description 2
- MLJJYUPMYNZYJW-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-2,6-dimethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(F)=CC(C)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 MLJJYUPMYNZYJW-UHFFFAOYSA-N 0.000 description 2
- VIGWCKLXTREABD-UHFFFAOYSA-N 8-[2-[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1 VIGWCKLXTREABD-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- OXPLANUPKBHPMS-ZXBNPROVSA-N desisobutyrylciclesonide Chemical compound C1([C@@H]2O[C@@H]3C[C@H]4[C@H]5[C@@H]([C@]6(C=CC(=O)C=C6CC5)C)[C@@H](O)C[C@@]4([C@@]3(O2)C(=O)CO)C)CCCCC1 OXPLANUPKBHPMS-ZXBNPROVSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002530 phenolic antioxidant Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- 125000004815 1,2-dimethylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([*:2])C([H])([H])[H] 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WGAGZUJPKROMTJ-UHFFFAOYSA-N 3-(3,5-ditert-butylphenyl)-2-hydroxypropanoic acid Chemical compound CC(C)(C)C1=CC(CC(O)C(O)=O)=CC(C(C)(C)C)=C1 WGAGZUJPKROMTJ-UHFFFAOYSA-N 0.000 description 1
- KGWYINKILPBKDX-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[1-(4-hydroxy-2,6-dimethylphenyl)-2-methylpropan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC1=CC(O)=CC(C)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 KGWYINKILPBKDX-UHFFFAOYSA-N 0.000 description 1
- OSJGFHCFUOVFPN-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(O)C=C1 OSJGFHCFUOVFPN-UHFFFAOYSA-N 0.000 description 1
- OGVVDHMJVKACDL-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(O)C=C1 OGVVDHMJVKACDL-UHFFFAOYSA-N 0.000 description 1
- KCEHVJZZIGJAAW-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 KCEHVJZZIGJAAW-UHFFFAOYSA-N 0.000 description 1
- XYFAENSVSMZYFX-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(2,4,6-trimethylphenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(C)=CC(C)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 XYFAENSVSMZYFX-UHFFFAOYSA-N 0.000 description 1
- QVMAEQWHZLHXRD-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(2,4,6-trimethylphenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.CC1=CC(C)=CC(C)=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 QVMAEQWHZLHXRD-UHFFFAOYSA-N 0.000 description 1
- SEVCOLOSQHILBC-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(4-propan-2-ylphenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C(C)C)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 SEVCOLOSQHILBC-UHFFFAOYSA-N 0.000 description 1
- LGFKWYRHQZIIOU-UHFFFAOYSA-N 6-hydroxy-8-[1-hydroxy-2-[[2-methyl-1-(4-propan-2-ylphenyl)propan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C1=CC(C(C)C)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 LGFKWYRHQZIIOU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DDQOJAMIFVBVFA-UHFFFAOYSA-N 8-[2-[[1-(2,4-difluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1F DDQOJAMIFVBVFA-UHFFFAOYSA-N 0.000 description 1
- BNROSTCVTBYDTE-UHFFFAOYSA-N 8-[2-[[1-(2,4-difluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1F BNROSTCVTBYDTE-UHFFFAOYSA-N 0.000 description 1
- DUPOKJDATDIUGO-UHFFFAOYSA-N 8-[2-[[1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1Cl DUPOKJDATDIUGO-UHFFFAOYSA-N 0.000 description 1
- GLDBFYYZFOBCPH-UHFFFAOYSA-N 8-[2-[[1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1Cl GLDBFYYZFOBCPH-UHFFFAOYSA-N 0.000 description 1
- FMUZEWZKZPSWHW-UHFFFAOYSA-N 8-[2-[[1-(3,4-difluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C(F)=C1 FMUZEWZKZPSWHW-UHFFFAOYSA-N 0.000 description 1
- BTTZFGJCUAEIOC-UHFFFAOYSA-N 8-[2-[[1-(3,5-dichlorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC(Cl)=CC(Cl)=C1 BTTZFGJCUAEIOC-UHFFFAOYSA-N 0.000 description 1
- UWQJICGNPSDFOS-UHFFFAOYSA-N 8-[2-[[1-(3,5-difluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC(F)=CC(F)=C1 UWQJICGNPSDFOS-UHFFFAOYSA-N 0.000 description 1
- WIRZALWOXMKWKJ-UHFFFAOYSA-N 8-[2-[[1-(3,5-difluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC(F)=CC(F)=C1 WIRZALWOXMKWKJ-UHFFFAOYSA-N 0.000 description 1
- MAUKZZRKCUYRAG-UHFFFAOYSA-N 8-[2-[[1-(3,5-dimethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(C)=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 MAUKZZRKCUYRAG-UHFFFAOYSA-N 0.000 description 1
- QCWDXENKQJNEKR-UHFFFAOYSA-N 8-[2-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(Cl)C(F)=C1 QCWDXENKQJNEKR-UHFFFAOYSA-N 0.000 description 1
- JLPFCLPUWJYNLF-UHFFFAOYSA-N 8-[2-[[1-(4-chlorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(Cl)C=C1 JLPFCLPUWJYNLF-UHFFFAOYSA-N 0.000 description 1
- JALKRHQYYXOVJR-UHFFFAOYSA-N 8-[2-[[1-(4-ethoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OCC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 JALKRHQYYXOVJR-UHFFFAOYSA-N 0.000 description 1
- OCYZWMPQWIYKIN-UHFFFAOYSA-N 8-[2-[[1-(4-ethoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C1=CC(OCC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 OCYZWMPQWIYKIN-UHFFFAOYSA-N 0.000 description 1
- LLQJQYIOQUUNMV-UHFFFAOYSA-N 8-[2-[[1-(4-ethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(CC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 LLQJQYIOQUUNMV-UHFFFAOYSA-N 0.000 description 1
- JQWKBKPGPPFEBE-UHFFFAOYSA-N 8-[2-[[1-(4-ethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.C1=CC(CC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 JQWKBKPGPPFEBE-UHFFFAOYSA-N 0.000 description 1
- DPZYHHDHCIPBLX-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-2-methylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(F)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 DPZYHHDHCIPBLX-UHFFFAOYSA-N 0.000 description 1
- YPLNROOLODMGQE-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-2-methylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one;hydrochloride Chemical compound Cl.CC1=CC(F)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 YPLNROOLODMGQE-UHFFFAOYSA-N 0.000 description 1
- GZAKTKZSVSNMGU-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-3,5-dimethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound CC1=C(F)C(C)=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 GZAKTKZSVSNMGU-UHFFFAOYSA-N 0.000 description 1
- FDAXQFAWUNASHA-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-3-methoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=C(F)C(OC)=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 FDAXQFAWUNASHA-UHFFFAOYSA-N 0.000 description 1
- WGKRKPHMWAQAEO-UHFFFAOYSA-N 8-[2-[[1-(4-fluoro-3-methylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=C(F)C(C)=CC(CC(C)(C)NCC(O)C=2C=3OCC(=O)NC=3C=C(O)C=2)=C1 WGKRKPHMWAQAEO-UHFFFAOYSA-N 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010053132 Lymphangiosis carcinomatosa Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- JKIJEFPNVSHHEI-UHFFFAOYSA-N Phenol, 2,4-bis(1,1-dimethylethyl)-, phosphite (3:1) Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC=C1OP(OC=1C(=CC(=CC=1)C(C)(C)C)C(C)(C)C)OC1=CC=C(C(C)(C)C)C=C1C(C)(C)C JKIJEFPNVSHHEI-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229920006226 ethylene-acrylic acid Polymers 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- COUYJEVMBVSIHV-UHFFFAOYSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119131 | 2006-08-18 | ||
| EP07101129 | 2007-01-25 | ||
| PCT/EP2007/058518 WO2008020057A1 (de) | 2006-08-18 | 2007-08-16 | Aerosolformulierung für die inhalation von betaagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ575425A true NZ575425A (en) | 2011-12-22 |
Family
ID=38521160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ575425A NZ575425A (en) | 2006-08-18 | 2007-08-16 | Aerosol formulation for the inhalation of beta agonists |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20080041369A1 (OSRAM) |
| EP (1) | EP2054084A1 (OSRAM) |
| JP (1) | JP2010501022A (OSRAM) |
| KR (1) | KR20090057393A (OSRAM) |
| AR (1) | AR062425A1 (OSRAM) |
| AU (1) | AU2007285747A1 (OSRAM) |
| BR (1) | BRPI0715761A2 (OSRAM) |
| CA (1) | CA2660488A1 (OSRAM) |
| CO (1) | CO6170341A2 (OSRAM) |
| IL (1) | IL197025A0 (OSRAM) |
| MX (1) | MX2009001759A (OSRAM) |
| NO (1) | NO20090407L (OSRAM) |
| NZ (1) | NZ575425A (OSRAM) |
| PE (1) | PE20081319A1 (OSRAM) |
| SG (1) | SG174058A1 (OSRAM) |
| TW (1) | TW200817011A (OSRAM) |
| UY (1) | UY30542A1 (OSRAM) |
| WO (1) | WO2008020057A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| JP5270343B2 (ja) * | 2005-08-15 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベータミメティックスの製造方法 |
| CN103501776A (zh) | 2011-02-17 | 2014-01-08 | 西普拉有限公司 | 甘罗铵与β2激动剂的组合物 |
| KR20140053307A (ko) | 2011-08-12 | 2014-05-07 | 베링거잉겔하임베트메디카게엠베하 | 맛이 차폐된 약제학적 조성물 |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| MX364652B (es) * | 2012-12-21 | 2019-05-03 | Boehringer Ingelheim Vetmedica Gmbh | Formulacion farmaceutica que comprende ciclesonida. |
| WO2014096115A1 (en) | 2012-12-21 | 2014-06-26 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
| DK3157522T3 (da) | 2014-06-18 | 2019-12-09 | Boehringer Ingelheim Vetmedica Gmbh | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste |
| US11701478B2 (en) | 2015-10-09 | 2023-07-18 | Boehringer Ingelheim International Gmbh | Method for coating microstructured components |
| CN115209884B (zh) * | 2020-01-20 | 2024-05-28 | 广州谷森制药有限公司 | 含有格隆溴铵和盐酸奥达特罗的可吸入制剂 |
| WO2021262675A1 (en) * | 2020-06-23 | 2021-12-30 | Anovent Pharmaceutical (U.S.), Llc | Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide |
| EP4188327B1 (en) | 2020-07-31 | 2025-05-28 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| CN117679423A (zh) | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE102004019540A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| US20050239778A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
| KR101287460B1 (ko) * | 2004-04-22 | 2013-07-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물 |
| DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| US7220742B2 (en) * | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| EP1778626A1 (en) * | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
-
2007
- 2007-08-15 UY UY30542A patent/UY30542A1/es not_active Application Discontinuation
- 2007-08-16 EP EP07819952A patent/EP2054084A1/de not_active Withdrawn
- 2007-08-16 MX MX2009001759A patent/MX2009001759A/es not_active Application Discontinuation
- 2007-08-16 US US11/839,809 patent/US20080041369A1/en not_active Abandoned
- 2007-08-16 AU AU2007285747A patent/AU2007285747A1/en not_active Abandoned
- 2007-08-16 KR KR1020097005575A patent/KR20090057393A/ko not_active Ceased
- 2007-08-16 PE PE2007001102A patent/PE20081319A1/es not_active Application Discontinuation
- 2007-08-16 JP JP2009525030A patent/JP2010501022A/ja active Pending
- 2007-08-16 SG SG2011057254A patent/SG174058A1/en unknown
- 2007-08-16 WO PCT/EP2007/058518 patent/WO2008020057A1/de not_active Ceased
- 2007-08-16 NZ NZ575425A patent/NZ575425A/en not_active IP Right Cessation
- 2007-08-16 BR BRPI0715761-4A2A patent/BRPI0715761A2/pt not_active IP Right Cessation
- 2007-08-16 CA CA002660488A patent/CA2660488A1/en not_active Abandoned
- 2007-08-17 AR ARP070103673A patent/AR062425A1/es not_active Application Discontinuation
- 2007-08-17 TW TW096130614A patent/TW200817011A/zh unknown
-
2009
- 2009-01-28 NO NO20090407A patent/NO20090407L/no not_active Application Discontinuation
- 2009-02-12 IL IL197025A patent/IL197025A0/en unknown
- 2009-03-18 CO CO09028168A patent/CO6170341A2/es not_active Application Discontinuation
-
2011
- 2011-11-11 US US13/294,449 patent/US20120058980A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG174058A1 (en) | 2011-09-29 |
| PE20081319A1 (es) | 2008-10-16 |
| IL197025A0 (en) | 2009-11-18 |
| KR20090057393A (ko) | 2009-06-05 |
| CA2660488A1 (en) | 2008-02-21 |
| JP2010501022A (ja) | 2010-01-14 |
| NO20090407L (no) | 2009-04-29 |
| BRPI0715761A2 (pt) | 2013-09-24 |
| UY30542A1 (es) | 2008-03-31 |
| US20120058980A1 (en) | 2012-03-08 |
| AU2007285747A1 (en) | 2008-02-21 |
| EP2054084A1 (de) | 2009-05-06 |
| MX2009001759A (es) | 2009-02-25 |
| TW200817011A (en) | 2008-04-16 |
| US20080041369A1 (en) | 2008-02-21 |
| WO2008020057A1 (de) | 2008-02-21 |
| CO6170341A2 (es) | 2010-06-18 |
| AR062425A1 (es) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080041369A1 (en) | Aerosol formulation for the inhalation of beta agonists | |
| US20080041370A1 (en) | Aerosol formulation for the inhalation of beta agonists | |
| US20100009984A1 (en) | Aerosol formulations for the inhalation of beta-agonists | |
| DK1809293T3 (en) | An aerosol formulation for inhalation of beta-agonists. | |
| CN101296700A (zh) | 吸入用气雾剂制剂 | |
| US20110281858A1 (en) | Aerosol formulation for the inhalation of beta agonists | |
| US20110319402A1 (en) | Aerosol formulation for the inhalation of beta agonists | |
| CN101505798A (zh) | 吸入用β-激动剂的气雾剂 | |
| HK1133831A (en) | Aerosol formulation for the inhalation of beta agonists | |
| HK1133830A (en) | Aerosol formulation containing beta agonists and steroids | |
| CN101505728A (zh) | 含β-激动剂和类固醇的气雾剂 | |
| HK1123750A (en) | Aerosol formulation for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |